Fraudsters stole $280 billion+ in COVID-19 relief funding: analysis
By
Kathleen Steele Gaivin
Jun 13, 2023
More than $280 billion in COVID-19 relief meant for businesses and individuals intentionally was stolen by fraudsters, and another $123 billion was wasted or misspent, according to an Associated Press...
FDA grants full approval to Paxlovid to treat COVID-19
May 25, 2023
Paxlovid has been taken by older adults and others at high risk for severe COVID-19 under an emergency use approval.
End of PHE a good time to review employee accommodations—carefully, EEOC says
By
Kathleen Steele Gaivin
May 17, 2023
The end of the COVID-19 public health emergency does not mean that employers can automatically terminate reasonable accommodations that were provided due to pandemic-related circumstances, the Equal Employment...
Researchers developing microneedle technology for painless vaccinations
By
Ryner Lai
May 11, 2023
British researchers say they are developing microneedle technology for vaccine delivery, potentially eliminating the need for painful vaccine injections.
Adverse postoperative outcomes not increased with recent COVID-19
Mar 28, 2023
The odds ratios for postoperative outcomes was not significantly increased for those with infection in preoperative days 1 to 30 and 31 to 60.
More testing of staff linked to drop in COVID-19 cases, deaths at SNFs
Mar 23, 2023
Reductions in COVID-19 cases and deaths among residents at skilled nursing facilities mainly were seen before vaccine availability.
Antibody response prolonged with COVID-19 vaccine-associated symptoms
Mar 20, 2023
An increased likelihood of experiencing a prolonged neutralizing antibody response was seen for those with vaccine-associated symptoms and prior SARS-CoV-2 infection.
FDA advisers back full approval of Paxlovid
Mar 17, 2023
The panel of FDA advisers says that the medication remains safe and effective for high-risk patients.
Minimal change in mental health linked to COVID-19
Mar 09, 2023
In general population studies, no change was observed in general mental health or anxiety symptoms; minimal worsening was seen in depression symptoms.
Natural protection against reinfection with BA.1 COVID-19 variant lower
Feb 17, 2023
However, protection against severe disease remains high, at 88.9%, for omicron BA.1 at 40 weeks.